Respiratory failure following isolated ziprasidone ingestion in a toddler.
Ziprasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar mania in adults and is used off label in children and adolescents. Despite increasing use of ziprasidone in both adult and pediatric populations, there remains a paucity of reports describing unintentional pediatric exposures. The following report describes a patient with isolated ziprasidone ingestion who required intubation secondary to respiratory failure. A 15-month-old previously healthy boy presented to the emergency department shortly after his father found him with approximately five partially dissolved 80-mg ziprasidone tablets in his mouth. The child was flaccid and lethargic with no eye opening, withdrawing from pain only. Two hours after arrival, he developed worsening CNS depression with inability to protect his airway and underwent endotracheal intubation. A serum ziprasidone level was 330 ng/mL by LC/MS. The patient was extubated approximately 14 h later and was discharged from the hospital shortly thereafter in good health without neurological sequelae. Isolated pediatric ingestion of ziprasidone resulting in the need for significant medical intervention has not been previously reported. We report a case of respiratory failure requiring intubation following accidental ziprasidone ingestion with confirmatory serum levels.
Gresham
Chip
C
Department of Medical Toxicology, Banner Good Samaritan Medical Center, Phoenix, AZ, USA. chipgresham@yahoo.com
Ruha
Anne M
AM
D000059:Accidents; D014150:Antipsychotic Agents / Q000097:blood / Q000506:poisoning*; D002853:Chromatography, Liquid; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage; D007223:Infant; D007442:Intubation, Intratracheal; D008297:Male; D013058:Mass Spectrometry; D008874:Midazolam / Q000008:administration & dosage; D010879:Piperazines / Q000097:blood / Q000506:poisoning*; D012121:Respiration, Artificial; D012131:Respiratory Insufficiency / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D013844:Thiazoles / Q000097:blood / Q000506:poisoning*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone; D008874:Midazolam